Ads
related to: keytruda cancer drug- Contact Us
Have Questions? Don’t Hesitate.
Contact Us Today.
- Precision Oncology
Finding Cancer's Fingerprint.
Learn More.
- NRG1 Fusion
More Aggressive Than You Think.
Learn About NGR1 Today.
- Genomic Landscape
Genomics are Changing the Future
of Oncology. Learn More.
- Contact Us
Search results
Merck to Buy Eye Drug Company Eyebiotech for Up to $3 Billion. It’s Doubling Down on Deals.
Barrons.com· 9 hours agoThe pharmaceutical company agrees to buy eye drug company Eyebiotech for up to $3 billion as it...
Merck to pay as much as $3 billion for eye treatment startup
Crain's New York Business· 7 hours agoWhile it raised its profit and sales forecast for the year on Keytruda sales, Merck has been on the...
Merck Nears $1.3 Billion Cash Deal for Eye-Drug Company EyeBio, WSJ Reports
US News & World Report· 20 hours agoMerck did not immediately respond to Reuters' request for a comment, while Eyebiotech declined to comment. Eyebiotech is a clinical stage opthalmology company, with operations in the U.S. and ...
Anti-Cancer Drug Pembrolizumab: Frequently Used Alone Or With Other Treatments
Forbes· 3 days agoPembrolizumab, sold as Keytruda by Merck & Co., was one of the first inhibitors to hit the market. A...
Clean Energy Ventures closes second funding round - The Boston Globe
The Boston Globe· 18 minutes agoChief executive Lauren Hobart has been expanding a new retail concept by renovating or relocating stores as House of Sport locations, with amenities such as batting cages and golf club repairs ...
Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports
Reuters via Yahoo Finance· 20 hours agoMerck has said it's in the market for deals of up to around $15 billion as it plans ways to deal...
TILT Biotherapeutics reports data from Phase I trial of ovarian cancer treatment
Clinical Trials Arena via Yahoo Finance· 1 day agoTILT-123 is an oncolytic adenovirus featuring tumour necrosis factor alpha (TNFα) and interleukin-2...
Merck to acquire eye drug company EyeBio for up to $3 billion
WSAU Wausau· 10 hours ago(Reuters) - Merck said on Wednesday it would acquire eye diseasedrug developer EyeBio for up to $3...
ASCO24: An early look at cancer drug study results
BioPharma Dive via Yahoo Finance· 6 days agoClinical trial abstracts posted Thursday ahead of this year’s ASCO meeting give a peek at anticipated datasets from Immunocore, Merus, J&J and Merck &...
Exclusive | Merck Nears $1.3 Billion Deal for Eye-Drug Company EyeBio
The Wall Street Journal· 20 hours agoSuch an acquisition would steer a company known for its cancer immunotherapy, Keytruda, into the...
Ads
related to: keytruda cancer drug
